• Affimed NV AFMD.OQ reported a quarterly adjusted loss of 94 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.60. The mean expectation of eight analysts for the quarter was for a loss of 94 cents per share. Wall Street expected results to range from €-1.07 to -76 cents per share.

• Revenue fell 92.1% to $155.00 thousand from a year ago; analysts expected $2.00 million.

• Affimed NV's reported EPS for the quarter was a loss of 94 cents​.

• The company reported a quarterly loss of €15.14 million.

• Affimed NV shares had risen by 11.6% this quarter and lost 40.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 17.9% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Affimed NV is 25.00

This summary was machine generated from LSEG data November 14 at 09:00 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)